Overview

Stiripentol in Dravet Syndrome

Status:
No longer available
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Stiripentol